Global Pet Cancer Therapeutics Market Segments 2024, Forecast To 2033
5 Mar, 2024
The pet cancer therapeutics market has shown rapid growth, increasing from $0.35 billion in 2023 to $0.39 billion in 2024, with a compound annual growth rate (CAGR) of 11.8%. This growth is attributed to the rise in pet ownership and advancements in veterinary medicine. Looking ahead to 2028, the market is expected to reach $0.59 billion, maintaining a 10.6% CAGR. The forecasted growth is linked to the growing aging pet population and the expansion of veterinary oncology services.
Global Pet Cancer Therapeutics Market Key Driver
Pet cancer therapeutics market growth is driven by increased pet healthcare expenditure. In the US, pet health insurance sees a 22% increase in the number of insured pets, reaching 4.8 million by 2022. Growing pet owners' willingness to invest in pet well-being contributes to the demand for pet cancer therapeutics, propelling market growth.
Get A Free Sample Of The Global Pet Cancer Therapeutics Market ReportGlobal Pet Cancer Therapeutics Market Segments
The pet cancer therapeutics market covered in this report is segmented –
1) By Cancer Type: Melanoma, Mast Cell Cancer, Lymphoma, Mammary And Squamous Cell Cancer
2) By Species: Dogs, Cats, Other Species
3) By Therapy: Chemotherapy, Radiation Therapy, Immunotherapy, TomoTherapy, Other Therapies
4) By End User: Veterinary Hospitals, Clinical Pharmacies, Retail Pharmacies, Online Pharmacies, Other End Users
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the pet cancer therapeutics market in 2023. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Pet Cancer Therapeutics Industry Players
AB Science; Boehringer Ingelheim GmbH; Elanco Animal Health; ELIAS Animal Health; Zoetis Inc.; Aratana Therapeutics Inc.; Anivive Lifesciences Inc.; QBiotics Group Ltd.; Regeneus Ltd.; VetDC Inc.; PetCure Oncology at Veterinary Radiosurgery and Imaging Center; Karyopharm Therapeutics Inc.; Torigen Pharmaceuticals Inc.; virology and bacteriology; Nippon Zenyaku Kogyo Co. Ltd.; Vivesto AB; Dechra Pharmaceuticals plc; Elekta Medical Systems India Pvt. Ltd.; Norbrook Laboratories Ltd.; AdvaVet Inc.; Merial Animal Health Ltd.; Oasmia Pharmaceuticals AB; Zenoaq Co. Ltd.; Rhizen Pharmaceuticals SA; Morphogenesis Inc.; Pfizer Inc.; Sumitomo Pharma Animal Health Co.; Vetivax; CarthroniX Inc.
Get The Full Global Pet Cancer Therapeutics Market Report
AIOps Pet Cancer Therapeutics Market Overview
Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. These therapeutics depend on several factors such as the type and stage of cancer, along with the pet's age and overall health.
Pet Cancer Therapeutics Global Market Report 2023 provides data on the global pet cancer therapeutics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The pet cancer therapeutics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.